BioCentury
ARTICLE | Clinical News

Daiichi ends Japanese development of Coherus' Enbrel biosimilar

July 7, 2017 8:40 PM UTC

Daiichi Sankyo Co. Ltd. (Tokyo:4568) discontinued development in Japan of CHS-0214 (BAX 2200), a biosimilar of Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN), to treat rheumatoid arthritis. Coherus BioSciences Inc. (NASDAQ:CHRS) said it regained territorial rights to the biosimilar.

Daiichi noted that CHS-0214 met the primary endpoint of equivalence to Enbrel in a trial to treat RA, but said it could not establish a “commercial manufacturing process to enable a feasible supply” of the product in Japan. Spokesperson Juliana Reed said Coherus is reviewing its plan for CHS-0214 in Japan...